The merger of Cambridge Antibody Technology and Oxford GlycoSciences won't, in the short term, solve many of the problems that both share--namely, a lack of products, scant clinical development capabilities and a non-existent sales and marketing infrastructure. It does, however, create a financially stronger potential acquiror in a European biotech industry in need of consolidation.
The management of monoclonal antibody company Cambridge Antibody Technology Group PLC (CAT) and
proteomics firm Oxford GlycoSciences PLC (OGS) are positioning their merger,
announced January 23, as a kind of inevitable marriage of two
compatible partners. After all, the biotech firms have been working
together since 2000 to develop a protein chip useful for screening
human monoclonal antibody libraries that CAT generates against OGS
proteomics targets [See Deal].
And in retrospect, it would appear that the two partners were preparing themselves for such a merger. Last year, struggling...
Candid conversations with C-suite leaders.
Keep up with strategy, innovation and evolving trends across life science industries.
BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.
Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.
The recent Women in Advanced Therapies Global event, delivered via an interactive 24-hour platform, hosted a number of biopharma speakers who drew on personal and industry-wide experiences, all aligned by a desire to break biases.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.